Risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) · people aged 18 and over undergoing vascular surgery
Summary of findings: Tranexamic acid showed no clear difference in risk of a thrombotic/thromboembolic event (MI, CVA, DVT, PE) compared with placebo (low certainty).
1 finding from 1 review
Red cell transfusion requirements (mL) ( · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people aged 18 and over undergoing vascular surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of reoperation or repeat procedure for bleeding within 7 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes risk of reoperation or repeat procedure for bleeding within 7 days compared with usual care (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).
1 finding from 1 review